ASTRAZENECA AND ASPEN COMPLETE ANAESTHETICS DEAL
1 November 2017 07:00 GMT ASTRAZENECA AND ASPEN COMPLETE AGREEMENT FORRESIDUAL RIGHTS TO ANAESTHETIC MEDICINES AstraZeneca today announced that it has completed the commercialisation agreement (announced 14 September 2017) with Aspen Global Incorporated (AGI), part of the Aspen Group, under which AGI has acquired the residual rights to established anaesthetic medicines comprising of Diprivan, EMLA, Xylocaine/Xylocard/